Belgium · Delayed Price · Currency is EUR Biotalys NV Statistics
Total Valuation
Biotalys NV has a market cap or net worth of EUR 114.07 million. The enterprise value is 103.26 million.
| Market Cap | 114.07M |
| Enterprise Value | 103.26M |
Important Dates
The last earnings date was Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotalys NV has 45.44 million shares outstanding. The number of shares has increased by 6.94% in one year.
| Current Share Class | 45.44M |
| Shares Outstanding | 45.44M |
| Shares Change (YoY) | +6.94% |
| Shares Change (QoQ) | +4.67% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 11.97% |
| Float | 23.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.62 |
| P/TBV Ratio | 7.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.93 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.21 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -96.43% and return on invested capital (ROIC) is -44.06%.
| Return on Equity (ROE) | -96.43% |
| Return on Assets (ROA) | -36.14% |
| Return on Invested Capital (ROIC) | -44.06% |
| Return on Capital Employed (ROCE) | -86.15% |
| Weighted Average Cost of Capital (WACC) | 11.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -441,237 |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -50,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.83% in the last 52 weeks. The beta is 1.37, so Biotalys NV's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -45.83% |
| 50-Day Moving Average | 2.81 |
| 200-Day Moving Average | 3.02 |
| Relative Strength Index (RSI) | 37.10 |
| Average Volume (20 Days) | 14,188 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.91M |
| Pretax Income | -16.82M |
| Net Income | -16.77M |
| EBITDA | -13.79M |
| EBIT | -14.91M |
| Earnings Per Share (EPS) | -0.44 |
Balance Sheet
The company has 14.04 million in cash and 3.24 million in debt, with a net cash position of 10.81 million or 0.24 per share.
| Cash & Cash Equivalents | 14.04M |
| Total Debt | 3.24M |
| Net Cash | 10.81M |
| Net Cash Per Share | 0.24 |
| Equity (Book Value) | 14.97M |
| Book Value Per Share | 0.38 |
| Working Capital | 10.22M |
Cash Flow
In the last 12 months, operating cash flow was -15.20 million and capital expenditures -119,000, giving a free cash flow of -15.32 million.
| Operating Cash Flow | -15.20M |
| Capital Expenditures | -119,000 |
| Depreciation & Amortization | 1.13M |
| Net Borrowing | -1.07M |
| Free Cash Flow | -15.32M |
| FCF Per Share | -0.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biotalys NV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.94% |
| Shareholder Yield | -6.94% |
| Earnings Yield | -14.70% |
| FCF Yield | -13.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Biotalys NV is 5.03, which is 103.64% higher than the current price. The consensus rating is "Buy".
| Price Target | 5.03 |
| Price Target Difference | 103.64% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |